195 related articles for article (PubMed ID: 35358872)
21. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.
Yang AD; Fan F; Camp ER; van Buren G; Liu W; Somcio R; Gray MJ; Cheng H; Hoff PM; Ellis LM
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4147-53. PubMed ID: 16857785
[TBL] [Abstract][Full Text] [Related]
22. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell.
Wang Z; Sun X; Feng Y; Wang Y; Zhang L; Wang Y; Fang Z; Azami NLB; Sun M; Li Q
Phytomedicine; 2021 Feb; 82():153414. PubMed ID: 33461143
[TBL] [Abstract][Full Text] [Related]
23. Nitrogen permease regulator-like 2 enhances sensitivity to oxaliplatin in colon cancer cells.
Liu MN; Liu AY; Du YJ; Pei FH; Wang XH; Chen J; Liu D; Liu BR
Mol Med Rep; 2015 Jul; 12(1):1189-96. PubMed ID: 25777765
[TBL] [Abstract][Full Text] [Related]
24. Overexpressed CES2 has prognostic value in CRC and knockdown CES2 reverses L-OHP-resistance in CRC cells by inhibition of the PI3K signaling pathway.
Zhang Y; Sun L; Sun Y; Chen Y; Wang X; Xu M; Chi P; Xu Z; Lu X
Exp Cell Res; 2020 Apr; 389(1):111856. PubMed ID: 31981591
[TBL] [Abstract][Full Text] [Related]
25. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism.
Lin S; Lei K; Du W; Yang L; Shi H; Gao Y; Yin P; Liang X; Liu J
Int J Biochem Cell Biol; 2016 Feb; 71():24-34. PubMed ID: 26673998
[TBL] [Abstract][Full Text] [Related]
27. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells.
Zhou C; Ji J; Shi M; Yang L; Yu Y; Liu B; Zhu Z; Zhang J
Mol Med Rep; 2014 Nov; 10(5):2729-35. PubMed ID: 25199623
[TBL] [Abstract][Full Text] [Related]
28. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
[TBL] [Abstract][Full Text] [Related]
29. The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK.
Yu M; Xu C; Zhang H; Lun J; Wang L; Zhang G; Fang J
Biochem Biophys Res Commun; 2021 Jul; 563():1-7. PubMed ID: 34052504
[TBL] [Abstract][Full Text] [Related]
30. Dihydromyricetin reverses MRP2-mediated MDR and enhances anticancer activity induced by oxaliplatin in colorectal cancer cells.
Wang Z; Sun X; Feng Y; Liu X; Zhou L; Sui H; Ji Q; E Q; Chen J; Wu L; Li Q
Anticancer Drugs; 2017 Mar; 28(3):281-288. PubMed ID: 27997436
[TBL] [Abstract][Full Text] [Related]
31. [Nrf2 down-regulated cell line H460-N5 with Keap1 over-expression increased sensitivity to anti-cancer drugs].
Qu LY; Gao P; Wang HY; Wang XJ; Tang XW
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Jan; 39(1):6-10. PubMed ID: 20175229
[TBL] [Abstract][Full Text] [Related]
32. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer.
Dong Y; Wang Z; Xie GF; Li C; Zuo WW; Meng G; Xu CP; Li JJ
Mol Cancer; 2017 Mar; 16(1):71. PubMed ID: 28356150
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs.
Sanders MA; Haynes B; Nangia-Makker P; Polin LA; Shekhar MP
J Biol Chem; 2017 Jun; 292(25):10347-10363. PubMed ID: 28490629
[TBL] [Abstract][Full Text] [Related]
34. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.
Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT
Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386
[TBL] [Abstract][Full Text] [Related]
35. Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines.
Liu Z; Qiu M; Tang QL; Liu M; Lang N; Bi F
Chin J Cancer; 2010 Jul; 29(7):661-7. PubMed ID: 20591218
[TBL] [Abstract][Full Text] [Related]
36. MiR-153-5p promotes sensibility of colorectal cancer cells to oxaliplatin via targeting Bcl-2-mediated autophagy pathway.
He Y; Zhang L; Tan F; Wang LF; Liu DH; Wang RJ; Yin XZ
Biosci Biotechnol Biochem; 2020 Aug; 84(8):1645-1651. PubMed ID: 32380907
[TBL] [Abstract][Full Text] [Related]
37. Decitabine exerted synergistic effects with oxaliplatin in colorectal cancer cells with intrinsic resistance to decitabine.
Hosokawa M; Tanaka S; Ueda K; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2019 Jan; 509(1):249-254. PubMed ID: 30581001
[TBL] [Abstract][Full Text] [Related]
38. Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivo.
Ozawa-Umeta H; Kishimoto A; Imaizumi A; Hashimoto T; Asakura T; Kakeya H; Kanai M
Cancer Sci; 2020 May; 111(5):1785-1793. PubMed ID: 32163218
[TBL] [Abstract][Full Text] [Related]
39. Luteolin Shifts Oxaliplatin-Induced Cell Cycle Arrest at G₀/G₁ to Apoptosis in HCT116 Human Colorectal Carcinoma Cells.
Jang CH; Moon N; Oh J; Kim JS
Nutrients; 2019 Apr; 11(4):. PubMed ID: 30987009
[TBL] [Abstract][Full Text] [Related]
40. Zuo Jin Wan Reverses the Resistance of Colorectal Cancer to Oxaliplatin by Regulating the MALAT1/miR-200s/JNK Signaling Pathway.
Wei Z; Zhou J; Yu H; Pu Y; Cheng Y; Zhang Y; Ji Q; Zhu H
Evid Based Complement Alternat Med; 2022; 2022():3032407. PubMed ID: 36248422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
